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Abstract
Aims Evidence on the association of macrophage- and neutrophil-related blood biomarkers with clinical outcome in heart
failure patients is limited, and, with the exception of C-reactive protein, no data exist on their temporal evolution. We aimed
to investigate whether temporal patterns of these biomarkers are related to clinical outcome in patients with stable chronic
heart failure (CHF).
Methods and Results In 263 patients with CHF, we performed serial plasma measurements of scavenger receptor cysteine-rich
type 1 proteinM130 (CD163), tartrate-resistant acid phosphatase type5 (TRAP), granulins (GRN), spondin-1 (SPON1), peptidoglycan
recognition protein 1 (PGLYRP1), and tissue factor pathway inhibitor (TFPI). The Cardiovascular Panel III (Olink Proteomics AB,
Uppsala, Sweden) was used. During 2.2 years of follow-up, we collected 1984 samples before the occurrence of the composite pri-
mary endpoint (PE) or censoring. For efficiency, we selected 567 samples for the measurements (all baseline samples, the last two
samples preceding the PE, and the last sample before censoring in event-free patients). The relationship between repeatedly mea-
sured biomarker levels and the PE was evaluated by joint models. Mean (±standard deviation) age was 67 ± 13 years; 189 (72%)
were men; left ventricular ejection fraction (%) was 32 ± 11. During follow-up, 70 (27%) patients experienced the PE. Serially mea-
sured biomarkers predicted the PE in a multivariable model adjusted for baseline clinical characteristics [hazard ratio (95% confi-
dence interval) per 1-standard deviation change in biomarker]: CD163 [2.07(1.47–2.98), P < 0.001], TRAP [0.62 (0.43–0.90),
P = 0.009], GRN [2.46 (1.64–3.84), P < 0.001], SPON1 [3.94 (2.50–6.50), P < 0.001], and PGLYRP1 [1.62 (1.14–2.31), P = 0.006].
Conclusions Changes in plasma levels of CD163, TRAP, GRN, SPON1, and PGLYRP1 precede adverse cardiovascular events in
patients with CHF.
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Introduction
The role of the immune system in heart failure is gaining atten-
tion.1 In general, the innate immune system provides a
non-specific defence against pathogens or tissue injury. It com-
prises various soluble molecules (e.g. complement system or
pentraxins) andmultiple cellular components, including antigen
presenting cells (e.g. dendritic cells), phagocytic cells (e.g.
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neutrophils and macrophages), and natural killer cells.2 These
immune cells express germ-line encoded pattern recognition
receptors (PRRs), which recognize pathogen-associated molec-
ular patterns (PAMPs) and damage-associated molecular pat-
terns 1 and either activate the NFkB pathway to increase the
expression of cytokines and interferons, or trigger formation
of inflammasome complexes which subsequently mediate the
production of interleukin-1Β and interleukin-18.3
In the context of heart failure, several types of PRRs have
been implicated in myocardial remodelling, including plasma-
and endosome-bound toll-like receptors type 4, as well as cy-
tosolic nucleotide-binding oligomerization domain (NOD)-like
receptors NOD containing protein 1 and NOD-, LRR- and
pyrin domain-containing protein 3.3,4 Additionally, activation
of the immune system may occur in extra-cardiac tissues as a
result of failure of the heart to maintain sufficient blood flow
and subsequent tissue damage. This systemic inflammation
may enhance unfavourable myocardial remodelling as well.5
For several heart failure-attributed biomarkers (such as
inflammatory-linked galectin-3, growth differentiation factor-
15, and tissue inhibitor of metalloproteinase-1), extra-cardiac
origins have been demonstrated.6
However, PRRs are only a part of the whole abundance of
molecules involved in the action of innate immune system,
which could play a role in myocardial remodelling and
failure. With this study, our main aim was to investigate
the relationship between clinical outcomes of heart failure
patients and serially measured plasma levels of molecules in-
volved in the actions of the innate immune system. In our
previous investigations, we have examined other compo-
nents of the proteomic multiplex panel by categorizing the
92 biomarkers based on their role in various processes
(cardiometabolic regulation, myocardial remodelling and
extracellular matrix turnover, fibrinolysis, and renal and pul-
monary function. The current analysis specifically includes
biomarkers related to the action of two cellular players of
the innate immune system: macrophages and, to a lesser ex-
tent, neutrophils. We describe cytokines and chemokines
elsewhere; moreover, we assigned those molecules that, be-
sides their function in the innate immunity, play important
roles in other processes, to the pathways listed above; such
as for example galectin-3 or suppression of tumorigenicity 2
.7–9 Here, we aim for a deeper understanding of innate
immune system dynamics in patients with heart failure
and to investigate the utility of macrophage- and
neutrophil-related molecules as biomarkers of prognosis in
these patients. Specifically, we examined the following
molecules that were available on a multiplex assay: peptido-
glycan recognition protein 1 (PGLYRP1; actions of neutro-
phils), scavenger receptor cysteine-rich type 1 protein
M130 (CD163), tartrate-resistant acid phosphatase type 5
(TRAP), granulins (GRN), and spondin-1 (SPON1) (macro-
phages) as well as tissue factor pathway inhibitor (TFPI) (tis-
sue response to aforementioned cells).
Methods
Chronic heart failure cohort
The Serial Biomarker Measurements and New Echocardio-
graphic Techniques in Chronic Heart Failure Patients Result
in Tailored Prediction of Prognosis (Bio-SHiFT) is a prospective
cohort study of stable patients with chronic heart failure
(CHF) conducted in Erasmus MC, Rotterdam, and Northwest
Clinics, Alkmaar, Netherlands. Ambulatory adult patients
were included if chronic heart failure had been diagnosed
according to European Society Guidelines at least 3 months
before and the clinical course was stable [i.e. they had not
been hospitalized for heart failure (HF) in the past 3 months].
Exact inclusion and exclusion criteria are presented in
Supporting Information Figure S1. The study was approved
by the medical ethics committees, conducted in accordance
with the Declaration of Helsinki,10 and registered in
ClinicalTrials.gov (NCT01851538). All the included patients
signed informed consent. Analyses presented in this article
comprised 263 patients with CHF enrolled during the first in-
clusion round period (October 2011 until June 2013).
Baseline assessment and follow-up procedures
All patients were evaluated by research physicians, who
collected information on HF-related symptoms and medical
history, and performed a physical examination. Patients were
categorized using National Kidney Foundation–Kidney Disease
Outcome Quality Initiative clinical practice guidelines on the
basis of glomerular filtration rate (GFR) estimated with the
chronic kidney disease epidemiology collaboration equation.
Study follow-up visits were predefined and scheduled ev-
ery 3 months (±1 month). Routine visits at the outpatient
clinic continued in parallel and were performed by the
treating physicians, who were blinded for biomarker results.
At each study follow-up visit, the research physician per-
formed a short medical evaluation, and blood samples were
collected. During follow-up, all medication changes and oc-
currence of hospitalizations for HF, myocardial infarction,
percutaneous coronary intervention, coronary artery bypass
grafting, arrhythmias, cerebrovascular accident, heart trans-
plantation, left ventricular assist device implantation, and
mortality, were recorded in the electronic case report forms,
and associated discharge letters were collected. Subse-
quently, a clinical event committee, blinded to the biomarker
results, reviewed hospital records and discharge letters and
adjudicated the study endpoints.
The primary endpoint (PE) was a composite of cardiac
death, heart transplantation, left ventricular assist device im-
plantation, and hospitalization for the management of acute
or worsened HF, whichever occurred first. Additionally, the
secondary endpoint consisting of cardiac death and
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hospitalization for the management of acute or worsened HF
was evaluated. We used the WHO International Classification
of Disease-10th revision, to assign the fatal endpoints. Car-
diac death was defined as death from myocardial infarction
or other ischemic heart disease (International Classification
of Disease-10th revision: codes I20-I25), death from other
heart disease-including HF (codes I30-I45 and I47-I52), sud-
den cardiac death (code I46), sudden death undefined (code
R96), or unwitnessed or ill-described death (codes R98, R99).
Hospitalization for acute or worsened HF was defined as a
hospitalization for an exacerbation of HF symptoms, in com-
bination with two of the following: BNP (Northwest Clinics)
or N-terminal pro BNP (NT-proBNP) (Erasmus MC) >3× upper
limit of normal (105 ng/L and 45 pmol/l, respectively), signs
of worsening HF, such as pulmonary rales, raised jugular ve-
nous pressure, or peripheral oedema, increased dose or intra-
venous administration of diuretics, or administration of
positive inotropic agents.11
Blood sampling
Blood samples were collected at baseline and at each tri-
monthly study follow-up visit. They were processed and
stored at 80°C within 2 h after collection until batchwise
biomarker measurement was performed after completion of
the follow-up. In the first inclusion round of the Bio-SHiFT
study that we used for the current investigation, we collected
a total of 1984 samples before occurrence of the PE or cen-
soring in 263 patients (median [25th–75th percentile] 9[5–
10] blood samples per patient). Our previous analyses using
all available samples in this cohort have demonstrated that
the concentration of several plasma and urine biomarkers
changes over the months preceding the incident adverse
event. For reasons of efficiency, for the current investigation,
we selected all baseline samples, the last sample available in
patients in whom the PE did not occur during follow-up, and
the two samples available closest in time prior to the PE. We
assumed that by selecting the last two samples prior to the
incident endpoint, we would capture the change in bio-
markers in patients with an event. Conversely, in event-free
patients, our previous investigations showed stable bio-
marker levels; in which case, one additional sample suffices.12
Altogether, our selection amounted to 567 samples for the
current analysis. All laboratory personnel were blinded for
clinical data and patient outcomes.
Laboratory measurements
The cardiovascular (cardiovascular disease) panel III of the
Olink Multiplex platform for new biomarkers (Olink Proteo-
mics AB, Uppsala, Sweden) was used for analysis of
high-abundance proteins. This platform enables simultaneous
measurement of multiple proteins in one plasma sample. The
proteins analysed by the assay were chosen based on their
potential to represent aspects of cardiovascular pathophysiol-
ogy. A unique feature of this particular multiplexing assay is
that it is based on proximity extension assay technology.13
The biomarkers are delivered in normalized protein expres-
sion (NPX) units, which are relative units that result from
the real-time polymerase chain reaction. They are expressed
on a log2 scale so that a one unit higher NPX value represents
a doubling of the measured protein concentrations. This arbi-
trary unit can thus be used for relative quantification of pro-
teins and for comparing fold changes between groups. In the
current analysis, CD163, TRAP, GRN, SPON1, PGLYRP1, and
TFPI were investigated, because these proteins are involved
in innate immune system functioning. Measurements below
the limit of detection were only observed in case of SPON1
(n = 38, 6.6% of all measurements).
Plasma NT-proBNP was analysed using an
electrochemiluminescence immunoassay (lower limit of de-
tection, LLD 5 ng/L, Elecsys 2010; Roche Diagnostics, India-
napolis, IN). High-sensitivity cardiac troponin T was also
measured using an electrochemiluminescence immunoassay
(LLD 3 ng/L, Elecsys 2010 immunoassay analyser; Roche Diag-
nostics, Indianapolis, IN). C-reactive protein (CRP) was
analysed using an immunoturbidimetric assay (LLD 0.3
mg/L, Roche Hitachi 912 chemistry analyser; Roche, Basel,
Switzerland). Creatinine was determined by a colorimetric
test by the Jaffe’s reaction in undiluted plasma (LLD: 0,14
mg/dL). All coefficients of variation of these four biomarkers
were below 5%.
Statistical analysis
Variables with a normal distribution are presented as mean ±
standard deviation (SD), whereas the median and interquar-
tile range (25th–75th percentile) are presented in case of
non-normality. Categorical variables are presented as counts
and percentages. For the analysis, in order to allow for direct
comparisons between different biomarkers we used the
Z-score (i.e. the mean was subtracted from the raw value,
subsequently divided by the SD) of the biomarker levels deliv-
ered in NPX units.
We evaluated the associations between baseline biomarker
levels and the PE with the use of univariable and multivariable
Cox proportional hazard regression models. We adjusted the
biomarker-outcome relation for age, sex, diabetes mellitus
(DM), atrial fibrillation (AF), baseline New York Heart Associa-
tion (NYHA) class, systolic blood pressure (SBP), estimated
GFR, and CRP. Then, we evaluated the associations between
repeated biomarker measurements and the PE with joint
models (JMs) thus combining the linear mixed effects (LME)
models for repeated measurements with relative risk models
for time-to-event data, including covariates as described
Macrophage- and neutrophil-related biomarkers in heart failure 3
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12678
above.14 Finally, we used time-dependent Cox models ad-
justed for the same covariates as in the JM and additionally ad-
justed for changing total daily equivalent doses of HF
medication used during follow-up (carvedilol, enalapril,
spironolactone, and furosemide), as defined in Table S2. Re-
sults are given as hazard ratios and 95% confidence intervals
per 1 SD difference of the biomarker level expressed in NPX
units. To plot the average temporal patterns of immune bio-
markers in patients with and without the PE, we also used
LME models. We applied the Bonferroni correction method
(threshold for P value: 0.008) to correct for multiple testing.
Additionally, we studied the associations of baseline charac-
teristics and routinely used biomarkers (NT-proBNP,
high-sensitivity troponin T, and CRP) with repeatedly mea-
sured immune biomarkers with the use of a LME model. Im-
mune biomarkers were entered as the dependent variables
and sampling time (fixed and random effect), baseline charac-
teristics (fixed effects), and routine biomarkers (fixed effects)
as the independent variables. All the investigated baseline
characteristics were concomitantly entered into one multivar-
iable model for each biomarker, so that any observed associa-
tions would be independent of the other characteristics. Here,
the conventional threshold was used for the P value (<0.05).
Data on all variables used in the models were complete, ex-
cept for SBP, which was missing in <5% of patients and for
which imputations were applied using the patients’ clinical
and outcome data. Adjusted and unadjusted models were
nested.
We have used the Panther Database to verify the molecu-
lar function and involvement in biological processes of the
biomarkers that we investigated.15
All tests were two-tailed. All analyses were performed with
R statistical software v. 3.4.1. using packages nlme v. 3.1-137
and JMbayes v. 0.8-71.
Results
Baseline characteristics and clinical outcomes
Mean age was 67 ± 13 years; 189 (72%) were men, 69 (26%) in
NYHA class III or IV, and mean left ventricular ejection fraction
(LVEF) was 32 ± 11%. Table 1 presents baseline characteristics
of the study population. Among baseline characteristics
analysed univariably with a Cox model, the following were as-
sociated significantly with the PE: age, NYHA class, DM, SBP,
NT-proBNP, high-sensitivity troponin T, CRP and diuretic dose,
as presented in Table S1.
Follow-up and study endpoints
During a median (interquartile range) follow-up of 2.2 (1.4–
2.5) years, a total of 70 (27%) patients reached the composite
PE: 56 of these 70 endpoints (80%) consisted of rehospitaliza-
tion for acute or worsened HF, 3 (4%) consisted of heart
transplantation, 2 (3%) of left ventricular assist device place-
ment, and 9 (13%) of cardiovascular mortality. The secondary
endpoint was observed in 65 patients.
Temporal evolution of immune biomarkers in
relation to study endpoints
The average temporal trajectories of immune biomarkers in
patients who experienced an incident endpoint and those
who did not are displayed in Figure 1. CD163, GRN, SPON1,
and PGLYRP1 increased prior to the occurrence of an end-
point, whereas TRAP decreased and TFPI level remained al-
most constant. At the same time, the biomarker levels
remained relatively stable or showed smaller change in
event-free patients.
Table 2 presents the associations of the immune bio-
markers with the PE. After adjustment for clinical covariates,
the occurrence of the PE was independently predicted by re-
peated measurements of CD163 (hazard ratio [95% confi-
dence interval] per 1 SD change of the biomarker level: 2.07
[1.47–2.98], P < 0.001, TRAP 0.60 [0.45–0.80], P < 0.001,
GRN 2.46 [1.64–3.84], P < 0.001, SPON1 (3.94 [2.50–6.50],
P < 0.001, and PGLYRP1 (1.62 [1.14–2.31], P = 0.006). These
associations persisted also after adjustment for changes in
medication dosage over follow-up and were valid also if only
patients with reduced ejection fraction (HF with reduced
ejection fraction) were analysed (effect estimates are
displayed in Table S5). The same set of repeatedly measured
biomarkers independently predicted the occurrence of
the secondary endpoint in both clinically- and
medication-adjusted models (Table S6). As the major etiologic
factor in our study population was ischemic heart disease, the
association between the investigated biomarkers and the PE
was evaluated separately in this subgroup, with CD163, TRAP,
SPON1, and PGLYRP1 showing independent predictive value
(Table S7). For the second-largest etiologic subgroup, dilated
cardiomyopathy, no associations could be demonstrated be-
tween baseline biomarker levels and the PE, and most of
the JMs did not converge properly probably because the size
of the subgroup was too small and the number of events too
low. Therefore, some estimates could not be calculated, and
those that are presented should be interpreted with reserva-
tion (Table S8).
Association between immune biomarkers and
baseline characteristics
Some of the baseline characteristics were independently as-
sociated with longitudinal patterns of the investigated bio-
markers (Table 3). Older age was associated with higher
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levels of TRAP and lower levels of in TFPI during follow-up.
Patients with DM and AF had higher CD163, GRN, and SPON1
during follow-up. Lower estimated GFR was associated with
higher GRN, SPON1, TFPI, and PGLYRP1. Table 3 also summa-
rizes the association between routinely used biomarkers and
immune biomarkers: a positive association was present be-
tween CRP and CD163, GRN, and SPON1; NT-proBNP showed
positive associations with GRN, SPON1, and PGLYRP1 and in-
verse associations with TRAP and TFPI, whereas higher tropo-
nin was associated only with higher PGLYRP1. Higher baseline
diuretics doses were associated positively with plasma
SPON1, whereas higher spironolactone dose was associated
with lower levels of CD163, GRN, SPON1, TFPI, and PGLYRP1.
Baseline values of immune biomarkers showed a moderate
degree of correlation in most cases, which can be observed
in Figure 2. Coefficient values are presented in Table S3.
The molecular function of the biomarkers and their involve-
ment in biological processes as derived from the Panther Da-
tabase is summarized in Table S4.
Discussion
In this prospective, observational study, we demonstrate that
the temporal evolutions of the investigated macrophage and
neutrophil-related biomarkers CD163, TRAP, GRN, SPON-1,
and PGLYRP-1 show significant and independent associations
with adverse clinical outcomes in CHF patients. Additionally,
we observe that these biomarkers reflect the severity of
heart failure as all of them, except for CD163, correlate with
NT-proBNP, and CD163 and SPON-1 are associated with
NYHA class. Based on these results, we conclude that the in-
vestigated molecules carry potential for prognostication.
They may therefore also potentially contribute to risk assess-
ment and even treatment optimization, such as medication
adjustment, earlier referral for interventional procedures
(e.g. valvular repair), or circulatory support.
The results of our study shed new light on the relevance of
these immune-related biomarkers, which were so far mostly
investigated in preclinical studies or with the use of single
measurements in clinical settings. We used a unique design
with repeated sampling, and we had samples available that
Table 1 Baseline characteristics of the study population (N = 263)
Variable Value
Demographics
Age (years) 67 ± 13
Male gender 189 (72)
Clinical characteristics
BMI (kg/m2) 27.5 ± 4.7
Systolic blood pressure (mmHg) 122 ± 20
Diastolic blood pressure (mmHg) 72 ± 11
Pulse (beat/min) 67 ± 12
Features of HF
LVEF, % 32 ± 11
NYHA class III or IV 69 (26)
Aetiology of HF
Ischemic heart disease 117 (44)
Hypertension 34 (13)
Secondary to valvular disease 12 (5)
Cardiomyopathy 68 (26)
Other or unknown 32 (12)
Medical history
Myocardial infarction 96 (37)
PCI 82 (31)
CABG 43 (16)
AF 106 (40)
Hypertension 120 (46)
Diabetes mellitus 81 (31)
Known hypercholesterolemia 96 (37)
COPD 31 (12)
KDOQI classification
eGFR ≥90 mL/min/1.73 m2 28 (11)
eGFR 60–89 mL/min/1.73 m2 95 (36)
eGFR 30–59 mL/min/1.73 m2 119 (45)
eGFR <30 mL/min/1.73 m2 21 (8)
Medication use
Beta-blocker 236 (90)
ACE-I or ARB 245 (93)
Aldosterone antagonist 179 (68)
Diuretic 237 (90)
Loop diuretics 236 (90)
Thiazides 7 (3)
Biomarker concentrations
Cardiac
NT-proBNP (pmol/L) 137.3 (51.7–272.6)
Hs-TnT (ng/L) 18.0 (9.5–33.2)
Inflammatory
CRP (mg/L) 2.2 (0.9–4.8)
Glomerular
Creatinine, mg/dl 1.18 (0.99–1.49)
eGFR-CKD EPI, mL/min per 1.73 m2 58 (43–76)
(Continues)
Table 1 (continued)
Variable Value
Immune response biomarkersa
CD163 6.24 (5.92–6.62)
TRAP 4.39 (4.16–4.65)
GRN 6.08 ± 0.41
SPON1 0.83 (0.66–1.13)
TFPI 8.23 (7.92–8.57)
PGLYRP1 7.17 ± 0.63
ACE-I, angiotensin-converting enzyme inhibitor; AF, atrial fibrilla-
tion; ARB, angiotensin II receptor blocker; BMI, body mass index;
CABG, coronary artery bypass grafting; CD163, scavenger receptor
cysteine-rich type 1 protein M130; COPD, chronic obstructive pul-
monary disease; CKD, chronic kidney disease; CRP, C-reactive pro-
tein; DBP, diastolic blood pressure; eGFR, estimated glomerular
filtration rate; GRN, granulins; Hs-TnT, high-sensitivity troponin T;
KDOQI, Kidney Disease Outcomes Quality Initiative; LVEF, left ven-
tricular ejection fraction; MI, myocardial infarction; NT-proBNP,
N-terminal prohormone of brain natriuretic peptide; PCI, percuta-
neous coronary intervention; PGLYRP1, Peptidoglycan recognition
protein 1 (TAG7); SBP, systolic blood pressure. SPON1, spondin-1;
TFPI, tissue factor pathway inhibitor; TRAP, tartrate-resistant acid
phosphatase type 5.
Categorical variables are expressed as count (percentage). Values
of continuous variables are expressed as mean ± standard devia-
tion or as median (interquartile range) in case of skewed
distribution.
aImmune biomarker concentrations in this table are given in arbi-
trary normalized protein expression (relative) units on a log2 scale.
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were drawn closely in time to the endpoint, an approach not
applied before in HF patients. We have also applied an ad-
vanced statistical method, joint modelling, that provides de-
tailed information on the temporal pattern of the biomarker
in association with clinical outcomes. This method is a first
step towards a personalized approach for prognostication,
as patient-specific biomarker evolution and associated prog-
nosis can easily be derived from the model.12 Additionally,
evaluating repeated measurements instead of baseline values
increases the statistical power. Effect estimates obtained
from models evaluating repeated measurements may be less
prone to attenuation after multivariable adjustment than es-
timates derived from models evaluating baseline measure-
ments in the same number of patients. This allowed us to
demonstrate the associations also after multivariable
adjustment in the models that contained repeated measure-
ments, contrary to models that used only baseline values.
Most of the molecules evaluated within our study are in-
volved in the actions of macrophages, and two of them
(SPON1 and PGLYRP1) are involved in the response to
damage-associated molecular patterns/PAMPs. SPON1 (F-
spondin), a molecule associated with adverse clinical outcome,
regulates migration and proliferation of macrophages in re-
sponse to CpG, a pattern typical for bacteria and recognized
by toll-like receptor 9 .16 In human studies, SPON1 was found
to correlate negatively with left ventricular ejection fraction17
and GFR in HF patients, which is in accordance with our re-
sults.18 SPON1 is also an independent predictor of HF and is as-
sociated with systolic dysfunction17 and was identified as a
candidate gene for hypertension based on an animal study.19
Figure 1 Average temporal evolution of biomarkers in patients during follow-up. Legend: x–axis: time remaining to the primary endpoint (for patients
who experienced adverse events) or time remaining to the last blood sampling (for patients who remained event free). ‘Time zero’ is defined as the
occurrence of the end point and is depicted on the right side of the x-axis, so that the average marker trajectory can be visualized as the end point
approaches (inherently to this representation, baseline sampling occurred before time zero). Y-axis: biomarker levels expressed as Z-score of normal-
ized protein expression. Solid red line: Average temporal pattern of biomarker level in patients who reached the primary end point during follow-up.
Solid blue line: Average temporal pattern of biomarker level in patients who remained end point free. Betas presented for patients who reached the
primary end point (red) and for patients who remained end point free (blue) per one year of follow-up based on linear mixed effects model. Dashed
lines: 95% confidence interval. Abbreviations: CD163, scavenger receptor cysteine-rich type 1 protein M130; GRN, granulins; PGLYRP1, peptidoglycan
recognition protein 1 (TAG7); SPON1, spondin-1; TFPI, tissue factor pathway inhibitor; TRAP, Tartrate-resistant acid phosphatase type 5.
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No evidence of its direct influence on cardiomyocytes is avail-
able so far, but SPON1 may be associated with several cardio-
vascular risk factors in this patient population.
Peptidoglycan, a bacterial wall component, belongs to
PAMPs recognized by intracellular Nod receptors, and four
types of secreted peptidoglycan recognition proteins,
PGLYRP-1-4. PGLYRP-1 (TAG7, peptidoglycan recognition pro-
tein short) is expressed in neutrophils and macrophages and
exhibits bactericidal properties via for example generation
of superoxide radicals.20 Multimers of PGLYRP-1 can also ac-
tivate a triggering receptor expressed on myeloid cells (trig-
gering receptors expressed on myeloid cells-1) without the
presence of peptidoglycan and enhance cytokine release.21
Further studies are necessary to evaluate its possible associa-
tion with heart muscle damage and verify whether its plasma
levels reflect a causal relationship or just the effect of comor-
bid atherosclerosis.22
CD163 is a member of the scavenger receptor cysteine-rich
superfamily and is exclusively expressed in monocytes and
macrophages. Levels of soluble CD163 reflect the amount of
its membrane-bound form, and soluble CD163 has been iden-
tified as a marker of anti-inflammatory M2 macrophage acti-
vation.23 M2 (CD14++CD16++) macrophages are responsible
for wound healing, neovascularization, and myofibroblast ac-
tivation. Their profibrotic action within the myocardium is
mediated by osteopontin,24 which we found to be associated
with adverse clinical outcome in our previous investigation.9
The levels of M2 macrophages are increased in asymptomatic
diastolic dysfunction, heart failure with preserved ejection
fraction,25 and HF with reduced ejection fraction.26 Based
on our study, CD163 plasma level increases prior to an ad-
verse clinical event, while the level in event-free patients re-
mains stable. Although the role of the molecule in HF still
needs further evaluation in mechanistic studies, we observed
for the first time that it is an independent predictor of clinical
outcome in a HF population.
TRAP, an iron-containing enzyme, resistant to inhibition by
tartrate and activated in acidic conditions, is highly expressed
in macrophages and was attributed a role in antigen process-
ing.27 With regard to cardiovascular disease, an association
between TRAP and lower risk of HF hospitalization in patients
with chronic kidney disease was observed previously,18 but it
remained unclear what mechanism could lead to this benefi-
cial effect. The authors suggested that this may be a result of
its inhibiting effect on osteopontin, which plays an important
role in the development of atherosclerosis, but also mediates
the profibrotic effect of M2 macrophages mentioned
above.24 The temporal changes of M2 macrophage bio-
marker CD163 and TRAP levels move in the opposing direc-
tions in the present dataset, which may reflect their
interplay on the molecular level. We observed that TRAP
levels are inversely associated with the occurrence of the
PE in the clinically adjusted model that is consistent with
the existing literature.Ta
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We also observed a positive association between GRN and
the PE. The assay we used is based on an antibody that binds
with progranulin (PGRN), a precursor protein that is later
cleaved into different GRN but also with GRN themselves.
Progranulin (proepithelin, granulin/epithelin precursor), a
pleiotropic growth factor, has not been investigated in heart
failure patients so far. It is highly expressed in epithelial cells,
neurons, and macrophages but also to a lesser extent in many
other types of cells.28 So far its role in malignancies, neurode-
generative and autoimmune diseases has been elucidated. Al-
though multiple immunity-related actions, both
pro-inflammatory and anti-inflammatory, of progranulin have
been described, its role is not fully understood so far.
For instance, progranulin competes with the strong
pro-inflammatory cytokine tumour necrosis factor-α by bind-
ing to its receptors type 1 and 2 and diminishes inflamma-
tion.29 On the other hand, progranulin cleavage products,
which include several types of GRN, may increase tumour ne-
crosis factor-α and IL-1β levels and therefore augment inflam-
mation.30 Unfortunately, in contrast to the abundance of data
on progranulin, there is a lack of evidence on specific GRN in
the literature. With the method used, we also cannot discrim-
inate between the impact of progranulin and its cleavage
products. Our results may be therefore viewed as hypothesis
generating and indicate a need for further studies. The equiv-
ocal role of progranulin is further illustrated by the fact that it
exerted a stimulatory effect on insulin resistance,31which goes
in line with our observation on higher GRN levels in diabetic
patients, but there is also evidence of its beneficial role in re-
ducing renal and cardiac damage in animal models.32,33
Together with the immune system biomarkers, we evalu-
ated a marker of tissue response to the activation of the im-
mune system. It has previously been reported that the
expression of anticoagulant TFPI is increased in response to
the tumour necrosis factor-α driven hypercoagulable state
within the myocardium.34 However, we did not observe an
association of TFPI with clinical outcome in our patients.
Apart from their potential for prognostication and even
treatment guidance and the mechanistic insights they pro-
vide, the investigated molecules may be also interesting as
therapeutic targets. Preclinical studies on antagonists of in-
nate immune receptors (TLR2 and toll-like receptors type 4)
and innate immune signalling pathways (myeloid differentia-
tion primary response 88, interleukin-1 receptor-associated
kinase 1, interleukin-1 receptor-associated kinase 4, and
NLRP3) have shown promising results, including a reduction
Figure 2 Network analysis of biomarkers depicting intermarker correlations.The thickness of the line between the biomarkers represents the correla-
tion coefficient (presented only if P < 0.05); a thicker line represents higher coefficients. Abbreviations: CD163, scavenger receptor cysteine-rich type 1
protein M130; GRN, granulins; PGLYRP1, peptidoglycan recognition protein 1 (TAG7); SPON1, spondin-1; TFPI, tissue factor pathway inhibitor; TRAP,
tartrate-resistant acid phosphatase type 5.
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in adverse left ventricular remodelling after acute myocardial
infarction.1 In this light, further evaluation of these innate
immunity-related molecules as therapeutic targets may be
of interest. We have shown that the functions of some of
the investigated molecules (TRAP, osteopontin, and M2 mac-
rophage biomarker CD163) are linked to each other. Such a
set of interrelated biomarkers could provide a tool for
‘mechanistic phenotyping’, that could potentially help us dis-
tinguish a subgroup of patients who would benefit from
anti-inflammatory treatment in a more reliable way than a sin-
gle biomarker. Such an approach has recently been applied
with several fibrotic biomarkers used for evaluation of re-
sponse to spironolactone in a post hoc analysis of the Treat-
ment of Preserved Cardiac Function Heart Failure With an
Aldosterone Antagonist trial.35Moreover, evaluation of a pos-
sible extra-cardiac origin of the investigated molecules may
shed some new light on their role, based on our observation
that levels of some of these biomarkers are higher in patients
with DM (CD163, GRN, and SPON1) and correlate inversely
with renal function (GRN, SPON1, TFPI, and PGLYRP1). Tissues
of interest could include adipose tissue, kidneys, or lungs.
Some aspects of this study warrant consideration. First,
this cohort consisted mainly of patients with HF with reduced
ejection fraction patients, and the results can therefore not
be extrapolated to CHF patients with preserved LVEF. Second,
concomitant measurement of monocyte subsets could have
yielded more information on the role of this selected group
of molecules. Third, the method we used does not allow us
to draw separate conclusions on progranulin and GRN.
In conclusion, the temporal evolution of innate immune
system biomarkers CD163, TRAP, GRN, SPON1, and PGLYRP1
is associated with adverse clinical endpoints in a CHF popula-
tion independently of traditional risk factors. These findings
suggest that these markers may be used to identify HF pa-
tients at increased risk of an adverse disease course.
Conflict of interest
Dominika Klimczak-Tomaniak, Elke Bouwens, Anne-Sophie
Schuurman, K. Martijn Akkerhuis, Alina Constantinescu,
Jasper Brugts, B. Daan Westenbrink, Jan van Ramshorst,
Tjeerd Germans, Leszek Pączek, Victor Umans, Eric Boersma,
and Isabella Kardys declare no conflict of interest.
Funding
The Bio-SHiFT study was supported by the Jaap Schouten
Foundation (Rotterdam, the Netherlands) and the Noordwest
Academie (Alkmaar, the Netherlands).
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Data S1. Appendix S1 - Supporting Information
Table S1. Univariable Cox model of baseline characteristics of
the study population.
Table S2. Medication dosage equivalents.
Table S3. Pearson correlation coefficients between the bio-
markers based on their first measurement.
Table S4. Molecular function of biomarkers and their involve-
ment in biological processes based on panther database
Table S5. Baseline and repeated biomarker measurements in
relation to the primary outcome in the subgroup of patients
with HF-REF (N = 250, N of events = 66)
Table S6. Associations of the biomarkers with the secondary
endpoint consisting of heart failure hospitalization and car-
diovascular death (N = 263, no. of events = 65)
Table S7. Associations of the biomarkers with the PE in pa-
tients with ischemic etiology of heart failure (N = 117, N of
events = 36).
Table S8. Associations of the biomarkers with the PE in pa-
tients with dilated cardiomyopathy (N = 49, N of events = 9).
Figure S1. Inclusion and exclusion criteria.
References
1. Mann DL. Innate immunity and the fail-
ing heart: the cytokine hypothesis
revisited. Circ Res 2015 Mar 27; 116:
1254–1268.
2. Ayoub KF, Pothineni NVK, Rutland J,
Ding Z, Mehta JL. Immunity, inflamma-
tion, and oxidative stress in heart fail-
ure: emerging molecular targets.
Cardiovasc Drugs Ther 2017 Dec; 31:
593–608.
3. Mezzaroma E, Toldo S, Farkas D,
Seropian IM, Van Tassell BW, Salloum
FN, Kannan HR, Menna AC, Voelkel NF,
Abbate A. The inflammasome promotes
adverse cardiac remodeling following
acute myocardial infarction in the
mouse. Proc Natl Acad Sci 2011; 108:
19725–19730.
4. Birks EJ, Felkin LE, Banner NR,
Khaghani A, Barton PJ, Yacoub MH.
Increased toll-like receptor 4 in the
myocardium of patients requiring
left ventricular assist devices. J
Heart Lung Transplant 2004 Feb; 23:
228–235.
5. Shah SJ, Kitzman DW, Borlaug BA,
van Heerebeek L, Zile MR, Kass DA,
Paulus WJ. Phenotype-specific treat-
ment of heart failure with preserved
ejection fraction: a multiorgan
10 D. Klimczak-Tomaniak et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12678
roadmap. Circulation 2016 Jul 5; 134:
73–90.
6. Du W, Piek A, Schouten EM, van de
Kolk CWA, Mueller C, Mebazaa A, Voors
AA, de Boer RA, Silljé HHW. Plasma
levels of heart failure biomarkers are
primarily a reflection of extracardiac
production. Theranostics 2018; 8:
4155–4169.
7. Bouwens E, Brankovic M, Mouthaan H,
Baart S, Rizopoulos D, van Boven N,
Caliskan K, Manintveld O, Germans T,
van Ramshorst J, Umans V, Akkerhuis
KM, Kardys I. Temporal patterns of
14 blood biomarker candidates of
cardiac remodeling in relation to
prognosis of patients with chronic heart
failure—the Bio- SH i FT study. J Am
Heart Assoc 2019 Feb 19; 8: e009555.
8. Brankovic M, Akkerhuis KM, Mouthaan
H, Brugts JJ, Manintveld OC, van
Ramshorst J, Germans T, Umans V,
Boersma E, Kardys I. Cardiometabolic
biomarkers and their temporal patterns
predict poor outcome in chronic heart
failure (Bio-SHiFT Study). J Clin
Endocrinol Metab 2018 Nov 1; 103:
3954–3964.
9. Brankovic M, Martijn Akkerhuis K,
Mouthaan H, Constantinescu A,
Caliskan K, van Ramshorst J, Germans
T, Umans V, Kardys I. Utility of temporal
profiles of new cardio-renal and pulmo-
nary candidate biomarkers in chronic
heart failure. Int J Cardiol 2019 Feb 1;
276: 157–165.
10. Rickham PP. Human experimentation.
Code of ethics of the World Medical As-
sociation. Declaration of Helsinki. Br
Med J 1964 Jul 18; 2: 177.
11. McMurray JJ, Adamopoulos S, Anker SD,
Auricchio A, BohmM,Dickstein K, Falk V,
Filippatos G, Fonseca C, Gomez-Sanchez
MA, Jaarsma T, Kober L, Lip GY,
Maggioni AP, Parkhomenko A, Pieske
BM, Popescu BA, Ronnevik PK, Rutten
FH, Schwitter J, Seferovic P, Stepinska
J, Trindade PT, Voors AA, Zannad F,
Zeiher A, Guidelines ESCCfP. ESC Guide-
lines for the diagnosis and treatment of
acute and chronic heart failure. The Task
Force for the Diagnosis and Treatment of
Acute and Chronic Heart Failure 2012 of
the European Society of Cardiology. De-
veloped in collaboration with the Heart
Failure Association (HFA) of the ESC.
Eur Heart J 2012, Jul; 33: 1787–1847.
12. Brankovic M, Akkerhuis KM, van Boven
N, Anroedh S, Constantinescu A, Caliskan
K, Manintveld O, Cornel JH, Baart S,
Rizopoulos D, Hillege H, Boersma E,
Umans V, Kardys I. Patient-specific evolu-
tion of renal function in chronic heart fail-
ure patients dynamically predicts clinical
outcome in the Bio-SHiFT study. Kidney
Int 2018 Apr; 93: 952–960.
13. Solier C, Langen H. Antibody-based pro-
teomics and biomarker research—cur-
rent status and limitations. Proteomics
2014 Mar; 14: 774–783.
14. Rizopoulos D. JM: An R package for the
joint modelling of longitudinal and
time-to-event data. J Stat Softw (Online)
2010; 35: 1–33.
15. Mi HMA, Ebert D, Huang X, Thomas PD.
PANTHER version 14: more genomes, a
new PANTHER GO-slim and improve-
ments in enrichment analysis tools.
Nucleic Acids Res 2019; 47: D419–D426.
16. Chen TA, Liao CC, Cheng YC, Chen YP,
Hsu YF, Liang CM, Liang SM. Stimula-
tion of proliferation and migration of
mouse macrophages by type B
CpG-ODNs Is F-Spondin and IL-1Ra De-
pendent. PLoS ONE 2015; 10: e0128926.
17. Stenemo M, Nowak C, Byberg L,
Sundstrom J, Giedraitis V, Lind L,
Ingelsson E, Fall T, Arnlov J. Circulating
proteins as predictors of incident heart
failure in the elderly. Eur J Heart Fail
2018 Jan; 20: 55–62.
18. Dubin RF, Whooley M, Pico A, Ganz P,
Schiller NB, Meyer C. Proteomic analysis
of heart failure hospitalization among
patients with chronic kidney disease:
The Heart and Soul Study. PLoS ONE
2018; 13: e0208042.
19. Clemitson JR, Dixon RJ, Haines S, Bing-
ham AJ, Patel BR, Hall L, Lo M, Sassard
J, Charchar FJ, Samani NJ. Genetic dis-
section of a blood pressure quantitative
trait locus on rat chromosome 1 and gene
expression analysis identifies SPON1 as a
novel candidate hypertension gene. Circ
Res 2007 Apr 13; 100: 992–999.
20. Lu X, Wang M, Qi J, Wang H, Li X, Gupta
D, Dziarski R. Peptidoglycan recognition
proteins are a new class of human bacte-
ricidal proteins. J Biol Chem 2006 Mar 3;
281: 5895–5907.
21. Read CB, Kuijper JL, Hjorth SA, Heipel
MD, Tang X, Fleetwood AJ, Dantzler JL,
Grell SN, Kastrup J, Wang C, Brandt
CS, Hansen AJ, Wagtmann NR, Xu W,
Stennicke VW. Cutting edge: identifica-
tion of neutrophil PGLYRP1 as a ligand
for TREM-1. J Immunol 2015 Feb 15;
194: 1417–1421.
22. Rohatgi A, Ayers CR, Khera A, McGuire
DK, Das SR, Matulevicius S, Timaran
CH, Rosero EB, de Lemos JA. The associ-
ation between peptidoglycan recogni-
tion protein-1 and coronary and
peripheral atherosclerosis: observations
from the Dallas Heart Study. Atheroscle-
rosis 2009 Apr; 203: 569–575.
23. Vogel DY, Glim JE, Stavenuiter AW, Breur
M, Heijnen P, Amor S, Dijkstra CD,
Beelen RH. Human macrophage polari-
zation in vitro:maturation and activation
methods compared. Immunobiology
2014 Sep; 219: 695–703.
24. Hulsmans M, Sager HB, Roh JD, Valero-
Munoz M, Houstis NE, Iwamoto Y, Sun
Y, Wilson RM, Wojtkiewicz G, Tricot B,
Osborne MT, Hung J, Vinegoni C,
Naxerova K, Sosnovik DE, Zile MR,
Bradshaw AD, Liao R, Tawakol A,
Weissleder R, Rosenzweig A, Swirski
FK, Sam F, Nahrendorf M. Cardiac mac-
rophages promote diastolic dysfunction.
J Exp Med 2018 Feb 5; 215: 423–440.
25. Glezeva N, Voon V, Watson C, Horgan S,
McDonald K, Ledwidge M, Baugh J.
Exaggerated inflammation and
monocytosis associate with diastolic dys-
function in heart failure with preserved
ejection fraction: evidence of M2 macro-
phage activation in disease pathogene-
sis. J Card Fail 2015 Feb; 21: 167–177.
26. Ptaszynska-Kopczynska K,
Marcinkiewicz-Siemion M, Lisowska A,
Waszkiewicz E, Witkowski M, Jasiewicz
M, Miklasz P, Jakim P, Galar B, Musial
WJ, Kaminski KA. Alterations of soluble
TWEAK and CD163 concentrations in
patients with chronic heart failure. Cyto-
kine 2016 Apr; 80: 7–12.
27. Halleen JM, Raisanen S, Salo JJ, Reddy
SV, Roodman GD, Hentunen TA,
Lehenkari PP, Kaija H, Vihko P, Vaananen
HK. Intracellular fragmentation of bone
resorption products by reactive oxygen
species generated by osteoclastic
tartrate-resistant acid phosphatase. J Biol
Chem 1999 Aug 13; 274: 22907–22910.
28. Jian J, Konopka J, Liu C. Insights into
the role of progranulin in immunity, in-
fection, and inflammation. J Leukoc Biol
2013 Feb; 93: 199–208.
29. Liu CJ. Progranulin: a promising thera-
peutic target for rheumatoid arthritis.
FEBS Lett 2011 Dec 1; 585: 3675–3680.
30. Okura H, Yamashita S, Ohama T, Saga
A, Yamamoto-Kakuta A, Hamada Y,
Sougawa N, Ohyama R, Sawa Y, Matsu-
yama A. HDL/apolipoprotein A-I binds
to macrophage-derived progranulin
and suppresses its conversion into proin-
flammatory granulins. J Atheroscler
Thromb 2010 Jun 30; 17: 568–577.
31. Youn BS, Bang SI, Kloting N, Park JW,
Lee N, Oh JE, Pi KB, Lee TH, Ruschke
K, Fasshauer M, Stumvoll M, Bluher M.
Serum progranulin concentrations may
be associated with macrophage infiltra-
tion into omental adipose tissue. Diabe-
tes 2009 Mar; 58: 627–636.
32. Fu Y, Sun Y, Zhou M, Wang X, Wang Z,
Wei X, Zhang Y, Su Z, Liang K, Tang W,
Yi F. Therapeutic potential of
progranulin in
hyperhomocysteinemia-induced
cardiorenal dysfunction. Hypertension
2017 Feb; 69: 259–266.
33. Nicoletto BB, Pedrollo EF, Carpes LS,
Coloretti NG, Krolikowski TC, Souza
GC, Goncalves LFS, Manfro RC, Canani
LH. Progranulin serum levels in human
kidney transplant recipients: a longitudi-
nal study. PLoSONE2018;13: e0192959.
34. Higuchi Y, Kubota T, Koyanagi M,
Maeda T, Feldman AM, Makino N. Up-
regulation of anticoagulant proteins,
protein S and tissue factor pathway in-
hibitor, in the mouse myocardium with
cardio-specific TNF-alpha overexpres-
sion. Am J Physiol Heart Circ Physiol
2012 Jun 1; 302: H2352–H2362.
35. Rossignol P, Ferreira JP, Zannad F. Fi-
brosis mechanistic phenotyping and
antifibrotic response determination
with biomarkers in heart failure:
one single biomarker may not fit all set-
tings. Eur J Heart Fail 2018 Sep; 20:
1300–1302.
Macrophage- and neutrophil-related biomarkers in heart failure 11
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12678
